Reviewer's report

**Title:** Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study

**Version:** 3  
**Date:** 2 February 2015  
**Reviewer:** Luca Porcu

**Reviewer's report:**

Minor Essential Revisions:
A) in Fig.1 censoring ticks should be explained in a legend; what do they mean?
B) rows n°118-120: "The adverse events were evaluated with Common Terminology Criteria for Adverse Events v4.0 (CECAE v4.0)". The word "CECAE" should be substituted with the word "CTCAE"
C) rows n°118-120: "The adverse events were evaluated with Common Terminology Criteria for Adverse Events v4.0 (CECAE v4.0)"; rows n°160-161: "Adverse events were assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0)". Which CTCAE grading scale was used (version 3.0 or version 4.0)? This inconsistency should be resolved.
D) rows n°143-144: "All patients received PSC with epirubicin 90 mg/143 m2 and cyclophosphamide 600 mg/m2 q3w followed by docetaxel 75 mg/m2 q3w."; but in table 1 four patients received an Anthracycline-based regimen as PSC therapy and three patients received a Taxane regimen followed by anthracycline-based regimen as PSC therapy; it seems that standard PSC was not administered to all patients enrolled in this feasibility trial.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I declare that I have no competing interests